Skip to content
Back to Search

Rachel K. Moore

photo placeholder

mrachel@uw.edu

Unpaid Academic

Child, Family, and Population Health Nursing

Grants
  • A participant- and investigator-blinded, randomized, placebo-controlled, multicenter, platform study to investigate efficacy, safety, and tolerability of various single treatments in participants with idiopathic pulmonary fibrosis, Novartis Pharmaceuticals Corporation
  • A PHASE III OPEN-LABEL EXTENSION STUDY TO EVALUATE LONG-TERM SAFETY AND EFFICACY OF PRM-151 IN PATIENTS WITH IDIOPATHIC PULMONARY FIBROSIS (IPF), Genentech, Inc.